Differential effects of parathyroid hormone, parathyroid hormone-related protein, and abaloparatide on collagen 1 expression by mouse cementoblasts and mouse tooth root density.

Autor: Hsu C; Formerly, Departments of Molecular Pathobiology and Orthodontics, New York University College of Dentistry, New York, NY; currently, Department of Orthodontics, Oregon Health Sciences University, Portland, OR., He Z; Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY., Le Henaff C; Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY., Partridge NC; Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY. Electronic address: ncp234@nyu.edu.
Jazyk: angličtina
Zdroj: American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics [Am J Orthod Dentofacial Orthop] 2023 Mar; Vol. 163 (3), pp. 378-388.e1. Date of Electronic Publication: 2022 Dec 19.
DOI: 10.1016/j.ajodo.2021.12.023
Abstrakt: Introduction: Parathyroid hormone (PTH) plays an important role in maintaining mineral homeostasis by regulating calcium and phosphate levels. Clinical trials have shown that peptides of PTH (1-34), PTH-related protein (PTHrP 1-36), and the new peptide modeled on PTHrP, abaloparatide, can have different anabolic effects on osteoporotic subjects, but the underlying mechanisms are still unclear. The prevalence of moderate and major gingival recession has been shown to be higher in postmenopausal women with osteoporosis. In addition, there is a significant association between osteoporosis and tooth loss.
Methods: We investigated the actions of these peptides on the cementoblasts and teeth of mice. The murine cementoblast line, OCCM-30, known to express collagen I (Col1a1), was treated with intermittent PTH (1-34), PTHrP (1-36), or abaloparatide for 6 h/d for 3 days. Microcomputed tomography was performed on the teeth of mice receiving daily injections of phosphate-buffered saline, PTH (1-34), or abaloparatide. Statistical differences were analyzed by a 2-way or 1-way analysis of variance followed by a Tukey's post-hoc test. Results are expressed as mean ± standard deviation, and P <0.05 was considered significant.
Results: Gene expression showed regulation of Bsp, Col1a1, Opg, Rankl, and Mmp13 by the 3 peptides in these cells. Western blots revealed that after intermittent treatment for 3 days, PTH (1-34) caused an increase in COL1A1 protein immediately after treatment. In contrast, abaloparatide showed a latent effect in increasing COL1A1 protein 18 hours after treatment. PTHrP had no effect on COL1A1 expression. Immunofluorescence confirmed the same result as the Western blots. Microcomputed tomography of teeth showed PTH (1-34) injections increased molar root mineral density in mice, whereas abaloparatide increased density in roots of incisors and molars.
Conclusions: This study reveals the differential anabolic effects of intermittent PTH (1-34), PTHrP (1-36), and abaloparatide on cementoblasts, as revealed by COL1A1 expression and root mineral density. Abaloparatide may be a potential therapeutic approach for achieving improved cementogenesis.
(Copyright © 2022 American Association of Orthodontists. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: